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Signaling networks downstream of receptor tyrosine
kinases are among the most extensively studied bio-
logical networks, but new approaches are needed
to elucidate causal relationships between network
components and understand how such relation-
ships are influenced by biological context and dis-
ease. Here, we investigate the context specificity of
signaling networks within a causal conceptual frame-
work using reverse-phase protein array time-course
assays and network analysis approaches. We focus
on a well-defined set of signaling proteins profiled
under inhibition with five kinase inhibitors in 32 con-
texts: four breast cancer cell lines (MCF7, UACC812,
BT20, and BT549) under eight stimulus conditions.
The data, spanning multiple pathways and com-
prising 70,000 phosphoprotein and 260,000 pro-
tein measurements, provide a wealth of testable,
context-specific hypotheses, several of which we
experimentally validate. Furthermore, the data pro-
vide a unique resource for computational methods
development, permitting empirical assessment of
causal network learning in a complex, mammalian
setting.
INTRODUCTION
The complexity of mammalian receptor tyrosine kinase (RTK)
signaling continues to pose challenges for the understandingCell Systems 4, 73–83, J
This is an open access article undof physiological processes and aberrations that are relevant
to disease. Networks, comprising nodes and linking directed
edges, are widely used to summarize and reason about
signaling. Obviously, signaling systems depend on the concen-
tration and localization of their component molecules, so
signaling events may be influenced by genetic and epigenetic
context (Saez-Rodriguez et al., 2011; Good et al., 2009; Zalatan
et al., 2012). In disease biology, and cancer in particular, an
improved understanding of signaling in specific contexts may
have implications for precision medicine by helping to explain
variation in disease phenotypes or therapeutic response.
Genomic heterogeneity in disease has been well studied,
notably in cancer, and heterogeneity is also manifested at the
level of differential expression of components of signaling path-
ways downstream of RTKs (Akbani et al., 2014; Gerlinger and
Swanton, 2010; Nickel et al., 2012; Szerlip et al., 2012). However,
differences in average protein abundance (as captured in differ-
ential expression or gene set analyses) are conceptually distinct
from differences in the edge structure of signaling networks, with
the latter implying a change in the ability of nodes to causally in-
fluence each other. Causal relationships are also fundamentally
distinct from statistical correlations: if there is a causal edge
from node A to node B, then the abundance of B may be
changed by inhibition of A, but A and B can be correlated with
no causal edge linking them (see below for an illustrative
example). For this reason, standard concepts from multivariate
statistics (that in turn underpin many network analyses in bioin-
formatics) may not be sufficient for causal analyses (Pearl, 2009).
Canonical signaling pathways and networks (as described, for
example, in textbooks and online resources) typically summarize
evidence from multiple experiments, conducted in different cell
types and growth conditions, and therefore, such networks are
not specific to a particular context. Many well-known links inanuary 25, 2017 ª 2016 The Authors. Published by Elsevier Inc. 73
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
such networks most likely hold widely, and so canonical net-
works remain a valuable source of insights. However, if causal
signaling depends on context, then using canonical networks
alone will neglect context-specific changes, with implications
for reasoning, modeling, and prediction. A large literature has
focused on the question of inferring molecular networks from
data (for reviews, see De Smet and Marchal, 2010; Marbach
et al., 2010). The potential for molecular networks to depend
on context has motivated efforts to tailor network models in a
data-driven manner (Marbach et al., 2016; Petsalaki et al.,
2015; Will and Helms, 2016). Our approach is in this vein but
with an emphasis on interventional data and a principled causal
framework. Unbiased ‘‘interactome’’ approaches (e.g., Rolland
et al., 2014) expand our view of the space of possible signaling
interactions. However, due to the nature of genetic, epigenetic,
and environmental influences, such approaches cannot in gen-
eral identify signaling events specific to biological context (e.g.,
specific to a certain cell type under defined conditions).
We study context-specific signaling using human cancer cell
lines. The data span 32 contexts, each defined by the combina-
tion of (epi)genetics (breast cancer cell lines MCF7, UACC812,
BT20, and BT549) and stimuli. In each of the 32 (cell line, stim-
ulus) contexts, we carried out time-course experiments using ki-
nase inhibitors as interventions (note that as used here, the inhib-
itors do not contribute to defining the context). Reverse-phase
protein arrays (RPPAs; Tibes et al., 2006) were then used to inter-
rogate signaling downstream of RTKs. We used more than
150 high-quality antibodies targeting mainly total and phosphor-
ylated proteins (see Table S1).
The inhibitors applied in each context allowed elucidation of
context-specific causal influences between inhibited and down-
stream phosphoproteins. The extent of context specificity seen
can be summarized as follows: on average, across all kinase in-
hibitors and pairs of contexts in the study, approximately one in
five phosphoproteins show changes in abundance under inhibi-
tion in one context that are not seen in the other. We also
modeled the data using recently developed methods rooted in
probabilistic graphical models to reconstruct context-specific
networks intended to capture causal interplay between all
measured phosphoproteins (and not just interplay related to in-
hibited nodes).
Thus, we show that causal signaling networks depend on
context, with the pattern of changes under inhibition dependent
on biological background. This is supported by independent vali-
dation experiments. Furthermore, we advance a conceptual
view of signaling networks as causal networks (Pearl, 2009). In
addition, this paper adds to available resources in two ways.
First, it provides a rich data resource, spanning all combina-
tions of context, inhibitor, and time and allowing for a very
wide range of analyses, including, but not limited to, analyses
of the kind presented here. The data complement available
patient datasets (see, for example, Akbani et al., 2014) by
providing interventional readouts under defined conditions and
provide a wealth of testable hypotheses regarding potentially
novel and context-specific signaling links. Second, the data
serve as a resource for computational biology benchmarking.
Network reconstruction has long been a core topic in computa-
tional biology, but performance with respect to learning of causal
links has mainly been benchmarked using simulated data that74 Cell Systems 4, 73–83, January 25, 2017may not adequately reflect the challenges of real data and rele-
vant biology. A previous study established a small, five-node
synthetic network in yeast that was valuable to the computa-
tional biology community, as it provided a gold-standard
network in a biological model (Cantone et al., 2009). The design
of our experiments allows for systematic testing of causal
network learning in a complex mammalian setting and provides
a unique resource for development of computational biology
methods. The data presented here were used in the recent
HPN-DREAM (Heritage Provider Network-Dialogue for Reverse
Engineering Assessment and Methods) network inference chal-
lenge. The challenge focused on causal networks, and the data
were used to score more than 2,000 submitted networks (full de-
tails of the challenge are described in Hill et al., 2016).
RESULTS
Causal Molecular Networks and Context Specificity
We first define causal molecular networks at a conceptual level.
Consider a specific cell line grown under defined conditions. We
refer to the complete biological setting (including genetic/epige-
netic background and growth/environmental conditions) as the
context c. If, in this setting, we observe a change in molecule
B under inhibition of molecule A, we can conclude that there ex-
ists a causal pathway (i.e., a sequence of mechanistic events,
possibly involving additional molecular species) between A and
B in context c. Conceptually, performing all possible inhibition
experiments on a set of molecules (including in combinations)
would allow construction of a directed network Gc, with nodes
corresponding to the molecules and edges encoding causal re-
lationships between nodes. Specifically, an edge in Gc indicates
that in context c, inhibition of the parent node can lead to a
change in the child node that is not mediated via any other
node in the network. We refer to Gc as the context-specific
causal network and to edges therein as causal edges (Figure 1A).
Due to the large number of potentially relevant molecular spe-
cies, it is likely that in any specific study, there will be variables
that are unmeasured but that nonetheless have a causal influ-
ence on one or more measured variables. Suppose there is no
causal pathway between A and B, but the nodes are correlated
due to co-regulation by an unobserved node C that is not repre-
sented in the graph (Figure 1B). Then, since inhibition of Awould
not be capable of changing B, an edge from A to B would not be
contained in the ground truth network Gc as defined above,
regardless of the strength of any correlation or statistical depen-
dence between A and B (Figure 1C). A contrasting case is that of
amissing variable that is intermediate in a causal pathway, e.g., if
A influences B via an unmeasured molecule C. Then, using the
definition above, we would consider the edge A/B to be a cor-
rect representation of the causal influence. However, if C were
observed, the correct model would be A/C/B (Figure 1C).
Thus, the definition we use is compatible with missing variables
while correctly encoding the effect of interventions on observed
nodes, but the edges are not intended to encode physically
direct influences only. We note that there are many subtle and
still open aspects of the epistemology of interventions and
causation; for a wider discussion, see Woodward (2016).
The definition of causal molecular networks above is rooted in
changes under inhibition but is not restricted to any particular
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Figure 1. Context-Specific Causal Net-
works
(A) Context-specific causal influences. NodeA has
a causal influence on node B in contexts c1 and c3,
but not c2, encoded by the presence of a causal
edge between A and B in c1 and c3 only. This re-
flects the outcome of experiments where A is in-
hibited. Here, each context is defined by the
combination of cell line and growth condition.
(B) Correlation and causation. The abundance of
node A is correlated with that of node B due to
regulation by the same node C. However, as there
is no causal influence (direct or indirect) of A on B,
inhibition of A does not result in a change in the
abundance of B, no matter how strong the corre-
lation or statistical dependence.
(C) Causal networks andmissing nodes. In the first
example, nodeC regulates both nodes A andB (as
in panel B). In the formulation used here, if C is not
observed and not included in the network, but
A and B are, we would regard the network with no
edge between A and B in either direction as the
correct or ground truth causal network, in line with
the results of experimental inhibition of these no-
des, as shown. In the second example, the un-
derlyingmechanism is thatA influencesC, andC in
turn influences B. In the formulation used here, if
C is not measured and not included in the network,
an edge from A to Bwould be regarded as correct,
in line with the results of experimental inhibition of
the nodes. However, if all three nodes were
included, the correct network would match the
underlying mechanism. Although abundance of
B changes under inhibition of A, an edge from A to
B would be regarded as incorrect here because
the influence ofA onB is fully mediated via another
network node (i.e.,C). See text for further details of
the causal formulation and its interpretation.mechanism. We focus on kinase inhibitors, phosphoprotein no-
des, and relatively short-term changes (up to 4 hr after inhibition),
and to that extent, our focus is on signaling, but we note that
changes seen in our data could be due to a number of mecha-
nisms, including transcription, translation, or protein stability. In
considering causal influences, it is important to specify a relevant
time frame, because under the same intervention, different
changes may occur over different time periods (see also Discus-
sion). Note also that even if one assumes a very large sample size
and neglects statistical issues entirely, a notion of magnitude (of
change under inhibition) remains implicit in the network definition
itself and influences the sparsity of the ground truth network.
Overview of Approach
We sought to investigate causal signaling networks in specific
biological contexts. We considered four breast cancer cell lines
(MCF7, UACC812, BT20, and BT549) derived from distinct
epigenetic states and harboring different genomic aberra-
tions (these cell lines have been extensively characterized; seeCBarretina et al., 2012; Garnett et al.,
2012; Heiser et al., 2012; Neve et al.,
2006). Each cell line was serum starved
for 24 hr and then at time t = 0 min stimu-lated with one of eight different stimuli (Figure 2A). For each
(cell line, stimulus) context, we carried out RPPA time-course as-
says comprising a total of seven time points spanning 4 hr and
under five different kinase inhibitors plus DMSO as a control
(Figure 2A; STAR Methods; the assays included additional,
later time points that were not used in our analyses but are avail-
able in Data S1). To ensure that targets of the kinase inhibitors
were effectively blocked, cells were treated with inhibitors for
2 hr before stimulus. Low concentrations of each inhibitor were
used to minimize off-target effects (see STAR Methods). Due
to the functional significance of phosphorylation, the analyses
presented below focus on the 35 phosphoproteins that were
measured in all cell lines (see STAR Methods and Table S1;
Data S1 contains measurements for all antibodies). Context-
specific changes under intervention were summarized as
‘‘causal descendancymatrices’’ (Figure 2B; see below).Machine
learning methods were used to integrate the interventional data
with known biology to reconstruct context-specific signaling net-
works (Figure 2C).ell Systems 4, 73–83, January 25, 2017 75
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Figure 2. Data-Driven Reconstruction of Context-Specific Causal Signaling Networks
(A) Overview of experimental approach. Reverse-phase protein arrays (RPPAs) were used to investigate protein signaling in four human breast cancer cell lines
under eight different stimuli. The combinations of cell line and stimulus defined 32 (cell line, stimulus) contexts. Prior to stimulus, cell lines were serum starved
and treated with kinase inhibitors or DMSO control. RPPA assays were performed for each context at multiple time points post-stimulus, using more than
150 high-quality antibodies to target specific proteins, including 40 phosphoproteins (the precise number of antibodies varies across cell lines; see STAR
Methods and Table S1).
(B) Causal descendancymatrices (CDMs). CDMs summarizing changes under intervention across all contexts were constructed for each intervention (see text for
details).
(C) Overview of causal network learning procedure. Interventional time-course data for each context were combined with existing biological knowledge in the
form of a prior network to learn context-specific phosphoprotein signaling networks. Networks were learned using a variant of dynamic Bayesian networks
designed for use with interventional data and that allowed joint learning over all 32 contexts at once (see STAR Methods).Interventional Time-Course Data Specific to Biological
Context
Comparing time-course data between inhibitor and control
(DMSO) experiments allowed us to detect changes to phospho-
protein nodes caused by kinase inhibition (see STAR Methods
for details). These changes are visualized in a global manner
for cell line MCF7 in Figure 3B, with DMSO time courses shown
in Figure 3A. In Figure 3B, the color coding indicates direction of
effect (see examples in Figure 3C): green indicates a decrease
under inhibition relative to control (consistent with positive regu-
lation) and red an increase under inhibition (consistent with nega-
tive regulation). Corresponding visualizations for UACC812,
BT20, and BT549 are shown in Figure S1.
Many effects, including many classical ones, are not stimulus
dependent. For example, phospho-p70S6K is reduced relative
to control under mTOR inhibition (inhibitor AZD8055; Figure 3C),
in line with the known causal role of mTOR in regulating phos-
phorylation of p70S6K. Since mTOR signaling is already active
in serum starved cells, the reduction in phospho-p70S6K under
mTOR inhibition is seen at all time points, including t = 0 min
(recall that the inhibitor is applied prior to stimulus). However,
some changes under intervention are specific to individual stim-76 Cell Systems 4, 73–83, January 25, 2017uli. Some of these effects can be readily explained, such as the
reduction in abundance of several phosphoproteins in the AKT
and mitogen-activated protein kinase (MAPK) pathways under
fibroblast growth factor receptor (FGFR) inhibition (inhibitor
PD173074) for cell line MCF7 stimulated with FGF1. Other stim-
ulus-specific changes are less expected, including the decrease
in abundance of phospho-AKT (phosphorylated at threonine
308) in cell lineMCF7 under inhibition ofmTOR and phosphatidy-
linositol 3-kinase (PI3K) (inhibitor BEZ235) that is observed in
only four of the stimuli.
Causal Descendancy Matrices Summarize Changes
under Intervention across Multiple Contexts
Changes seen under inhibition of mTOR (catalytic inhibitor
AZD8055) are summarized in Figure 4A (with phosphoproteins
in rows and the 32 contexts in columns). Here, a filled-in box for
phosphoprotein p in context c indicates a salient change under
mTOR inhibition (seeSTARMethods), consistentwith a causal in-
fluence of mTOR on phosphoprotein p in context c. This could
occur via a causal pathway involving other (measured or unmea-
sured) nodes. In other words, an entry in location (p,c) in the ma-
trix indicates that phosphoprotein p is a descendant of mTOR in
AC
B
Figure 3. Phosphoprotein Time-Course Data and Context-Specific Changes under Inhibition for Breast Cancer Cell Line MCF7
(A) Phosphoprotein time courses under DMSO control. Rows correspond to 35 phosphoproteins (a subset of the full set of 48; see STARMethods for details) and
columns correspond to the eight stimuli. Each time course shows log2 ratios of phosphoprotein abundance relative to abundance at t = 0. Shading represents
average log2 ratio for t > 0.
(B) Phosphoprotein time courses under kinase inhibition. Each of the five vertical blocks corresponds to a different inhibition regime. Within each block, rows and
columns are as in (A). Each time course shows log2 ratios of phosphoprotein abundance under inhibition relative to abundance under DMSO control. Shading
represents direction of changes in abundance due to inhibitor: Green denotes a decrease in abundance, red denotes an increase and gray denotes no salient
change (see examples in C). See STAR Methods for details of statistical analysis. For both (A) and (B), plots were generated using a modified version of the
DataRail software (Saez-Rodriguez et al., 2008). Each phosphoprotein is plotted on its own scale, and phosphoproteins are ordered by hierarchical clustering of
all data. See Figure S1 for corresponding plots for cell lines UACC812, BT20, and BT549.
(C) Selected examples from (B) showing control (DMSO) and inhibitor time courses separately; box color identifies the source cell in (B). Examples are shown for
(from left to right) a clear decrease in abundance, a clear increase in abundance, a decrease in abundance that is borderline under the criteria we use, a borderline
case called negative (i.e., called as no change), and a clear negative case. Shaded region indicates time-averaged replicate SD. See also Figure S2.the causal networkGc for context c; we therefore refer to thisma-
trix as a causal descendancy matrix for mTOR. For comparison,
an additional column shows proteins that are descendants of
mTOR according to a canonical signaling network (Figure 4B;
STAR Methods). Many classical signaling links are conserved
across cell lines and stimuli, but there are also many examples
of influences that are both non-canonical and context-specific.
For example, phospho-p38 is elevated in UACC812 cells treated
with the mTOR inhibitor AZD8055 under serum stimulation,
whereas there is no change in BT549 cells under the same condi-tions. Similarly, we obtained causal descendancy matrices for
each of the other inhibitors in our study (Figure S3). On average
across all kinase inhibitors andpairs of contexts, 8 out of 35phos-
phoproteins show salient changes under inhibition in one context
that are not seen in theother (meannumber of differences=8.14).
Considering only pairs of cell lines under the same stimulus, the
mean number of differences is 8.58, while considering pairs of
stimuli for the same cell line, the corresponding value is 6.38.
This suggests that the differences in (epi)genetic background
between the cell lines have a relatively pronounced effect.Cell Systems 4, 73–83, January 25, 2017 77
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(A) Causal descendancy matrix showing causal effects observed under mTOR inhibitor AZD8055 in each of the 32 (cell line, stimulus) contexts. Rows represent
phosphoproteins and columns represent contexts (see Figure 3). Black boxes indicate phosphoproteins that show a salient change under mTOR inhibition in a
given context (see STAR Methods) and can therefore be regarded as causal descendants of mTOR in the signaling network for that context. The final column on
the right indicates phosphoproteins that are descendants of mTOR in the canonical mTOR signaling pathway shown in (B). Phosphoproteins are ordered first by
canonical column and then by hierarchical clustering of all data. See Figure S3 for causal descendancy matrices for the other inhibitor regimes.
(B) Canonical mTOR signaling pathway. Blue nodes are descendants of mTOR in the network, and white nodes are non-descendants. The pathway shown is a
subnetwork of the prior network used within the network inference procedure (Figure S4). Full nodes names, including phosphorylation sites, are provided in
Table S4.
(C) Summary of western blot validations of causal effects observed in RPPA data. A number of observations from the causal descendancy matrices were chosen
for validation via western blot analysis. The number of phosphoprotein validations attempted (‘‘Tested’’) and the number of these that successfully validated
(‘‘Validated’’) are presented for various (cell line, stimulus, inhibitor) combinations. Summary totals are also presented for each cell line, each inhibitor, and across
all validation experiments. See also Table S2.We sought to validate some of the observed causal effects by
western blot analysis (STAR Methods). Observations were
selected for validation across both inhibitors and antibodies,
and included instances of increase and decrease under inhibi-
tion, as well as instances where no effect was observed (Table
S2). A summary of the number of observations tested for each
cell line and inhibitor regime and of validation success rate in in-
dependent experiments (i.e., new lysates) is shown in Figure 4C.
Overall, we validated 78% of observations tested (104 out of 134
observations). There were 25 (antibody, inhibitor) combinations
that for the same stimulus showed differing effects across cell
lines in the RPPA data (and which were also tested by western78 Cell Systems 4, 73–83, January 25, 2017blotting); 17 of these instances of heterogeneity across cell lines
validated (68%). The corresponding validation rate for (antibody,
inhibitor) combinations that for the same cell line showed
differing effects across stimuli was only 3 out of 13 (23%). Fail-
ures to validate could represent biological variability, differential
sensitivity between RPPA and western blotting, use of different
antibodies, or other technical issues.
Machine Learning of Signaling Networks
We used dynamic Bayesian networks to learn context-specific
causal networks over all measured phosphoprotein nodes
(including those not intervened upon). To do so, we exploited
BT20 In prior                Not in priorUACC812 MCF7 BT549 All cell lines
Figure 5. Context-Specific Signaling Networks Reconstructed Using a Machine Learning Approach
Data for 35 phosphoproteins were analyzed using a machine learning approach based on interventional dynamic Bayesian networks, integrating also known
biology in the form of a prior network (Figure S4). This gave a set of scores (edge probabilities) for each possible edge in each (cell line, stimulus) context (see STAR
Methods). For each cell line, a summary network was obtained by averaging edge probability scores across the eight stimulus-specific networks for that cell line.
Edge color denotes cell line. Only edges with average probabilities greater than 0.2 are shown. A black edge indicates an edge that appears (i.e., is above the
0.2 threshold) in all four cell lines. Edge thickness is proportional to the average edge probability (average taken across all 32 contexts for black edges). Solid or
dashed edges were present or not present in the prior network, respectively. Edges are directed with the child node indicated by a circle. Edge signs are not
reported; the modeling approach does not distinguish between excitatory and inhibitory causal effects. Full node names, including phosphorylation sites, are
provided in Table S4. Network visualized using Cytoscape (Shannon et al., 2003). See also Table S3.several recent methodological advances that allow integration of
interventional data and simultaneous network learning across
multiple related problem instances (here, contexts; see STAR
Methods and references therein for details). Known biology
was incorporated using a prior network (Figure S4).
Figure 5 summarizes networks across all contexts by aver-
aging across the eight stimulus-specific networks for each of
the four cell lines. We see that while many edges, including
several classical ones, are near universal, others are cell line
specific, mirroring, via a global analysis, the inhibition data re-
ported above (Figure 4A). The networks contained edges
included in the prior network as well as many edges that were
not. Across the 32 contexts, networks contained an average of
49 edges (at a threshold of 0.2 applied to the edge probabilities
that are the output of the learning procedure) and, on average,
40% of edges in each network were not in the prior network (Ta-
ble S3). We discuss potentially novel edges that were not in the
prior below. As discussed in Hill et al. (2016), the challenging na-
ture of causal network learning means that empirical perfor-
mance assessment is important. We used an extended variant
of the train-and-test procedure described in Hill et al. (2016) to
systematically assess causal network learning (see STAR
Methods). We found that the models were able to achieve signif-
icant agreement with unseen test interventional data in most of
the contexts (Figure S5). However, we note that empirical
assessment is a frontier topic in causal inference, and theassessment procedure used here is subject to a number of ca-
veats (see Discussion).
Validation of Context-Specific Signaling Hypotheses
We identified 235 edges in the inferred networks that were not
in the prior network. These potentially novel edges shared
35 parent proteins, 4 of which were inhibited in the original data-
set. Five edges with parent nodes not among those inhibited in
the original RPPA data were selected for validation by western
blot. Edge selection was done on the basis of biological interest
and availability of sufficiently specific inhibitors for the parent no-
des (Figure 6). We note that our computational approach pre-
dicts presence/absence of each (directed) edge, but not sign
(activating or inhibiting).
For each of the five edges, we tested contexts in which the
edge was predicted as well as those in which the edge was
not predicted. We inhibited the parent node and observed
whether this altered abundance of the predicted child node.
We found evidence supporting each of the five predicted causal
edges, but with often-complex context dependence. These re-
sults, and their agreement and disagreement with context-spe-
cific predictions from network modeling, are summarized in Fig-
ures 6F and 6G.
An edge from Chk2_pT68 to p38_pT180/Y182 (for phospho-
proteins, we give the protein name before an underscore, which
is followed by the phosphorylation site or sites) was predictedCell Systems 4, 73–83, January 25, 2017 79
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Figure 6. Validation of Novel Network Edges
Western blot analysis of selected context-specific network edges that were not in the prior network. (A–E) Edges tested were (A) phospho-Chk2 to phospho-p38,
(B) phospho-p38 to phospho-JNK, (C) phospho-Src to phospho-NF-kB, (D) phospho-p70S6K to phospho-p27, and (E) phospho-Chk2 to phospho-YAP. Orange
boxed areas indicate observed changes in abundance of the predicted child node under inhibition of the parent node in a single (cell line, stimulus) context
(changes in abundance are determined by visual inspection of the bands). Edge probabilities output by the network learning procedure are shown for each
context tested (‘‘edge strength’’).
(F) A summary of the validation experiments. NA denotes not applicable (the experimentwas not run), andNEdenotes no effect (therewas no change in child node
abundance upon inhibition of the parent node). An arrow indicates results consistent with an activating parent node. A stunted line represents results consistent
with an inhibitory edge. Symbols are colored orange to indicate that an edge was predicted for the corresponding cell line under one of the stimuli tested.
(legend continued on next page)
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only in cell line BT549 (Figure 5). We inhibited Chk2 with
AZD7762 in BT549 cells and saw decreases in phospho-p38
under serum (fetal bovine serum [FBS]) and neuregulin (NRG)1,
where the edge was predicted, as well as under insulin, where
the edge was not predicted (Figure 6A). In contrast, there is no
change in phospho-p38 in BT20 cells under AZD7762 treat-
ment, consistent with the absence of the edge in the BT20
networks. Here, we see that the edge validates in a cell line-
specific, but not stimulus-specific, manner. However, it is impor-
tant to note that AZD7762 inhibits Chk1 and Chk2 with equal
potency and also demonstrates activity, albeit lower, against
other kinases.
The networks predicted an edge from p38_pT180/Y182 to
JNK_pT183/T185 in BT549 and BT20 cells under stimulus with
FBS. We inhibited p38 with VX702 in BT549, BT20, and
UACC812 cells stimulated with FBS. In line with network predic-
tions, we observed an increase in phospho-JNK in BT549 and
BT20 cells (Figure 6B), but we also observed a modest increase
in phospho-JNK in UACC812 cells, where the edge was not
predicted.
An edge from Src_p416 to nuclear factor (NF)-kB-p65_pS536
was predicted only in BT20 cells stimulated with epidermal
growth factor (EGF). Upon inhibition of Src with KX2391 both
before and after stimulation with EGF, an increase in the abun-
dance of phospho-NF-kB was observed in BT20 cells, consis-
tent with the presence of a causal link (Figure 6C). The connec-
tion between phospho-Src and phospho-NF-kB was also
observed in MCF7, where the edge was not predicted.
An edge from p70S6K_pT389 to p27_pT198 was predicted in
all of the UACC812 and BT549 networks. The edgewas also pre-
dicted in MCF7 networks for PBS, insulin, FGF, NRG1, and insu-
lin-like growth factor (IGF)1 and in the BT20 NRG1 network.
When p70S6K was inhibited in UACC812 cells with PF4708671,
a change in phospho-p27 was observed only at the zero time
point before stimulus was added (Figure 6D). In MCF7 cells stim-
ulated with hepatocyte growth factor (HGF), phospho-p27
decreased in abundance under p70S6K inhibition; however, the
edgewasnot predicted in this context.WhenPF4708671-treated
MCF7 cells were stimulatedwith IGF, a context in which the edge
was predicted with high probability, no change in phospho-p27
was observed. Similarly, there was no change in phospho-p27
in BT20 cells that had been treated with PF4708671 and stimu-
lated with HGF.
In BT549, an edge was predicted from Chk2_pT68 to
YAP_pS127 under HGF and insulin. BT549 cells treated with
the Chk2 inhibitor AZD7762 exhibit an increase in phospho-
YAP (Figure 6E). This edge was not predicted in any other cell
line tested. However, in both UACC812 and MCF7 cells treated
with AZD7762, a decrease in the abundance of phospho-YAP is
observed. Active Chk2 appears to decrease phospho-YAP in
BT549 cells (where the edge was predicted) and increase phos-
pho-YAP in UACC812 and MCF7 cells (where the edge was not
predicted). These results are consistent with the existence of a(G) Summary of agreement and disagreement between predicted edges and va
showed evidence for the edge in a (cell line, stimulus) context in which it was predi
each edge, respectively. A green tick denotes specificity in (partial) agreement wit
in agreement with predictions in terms of the precise contexts in which effects
validation experiments, despite being predicted by the networks.causal influence of phospho-Chk2 on phospho-YAP in all of
these cell lines and not just in BT549 as predicted.
DISCUSSION
The data and analyses presented here support the notion that
causal molecular networks can depend on context. We focused
on signaling proteins and breast cancer cell lines. The cell lines
represent contexts that are genetically perturbed but with a
shared cancer type. The heterogeneity that we observed in
causal networks suggests that substantial differences could
exist between, for example, samples from different tissue types
or divergent environmental conditions. This strongly argues for a
need to refine existing regulatory models for specific contexts,
not least in disease biology.
Given the range of potentially relevant contexts—spanning
combinations of multiple factors, including genetic, epigenetic,
and environmental—we do not believe that characterization of
causal networks across multiple contexts can feasibly be done
using classical approaches in a protein-by-protein manner.
Rather, it will require high-throughput data acquisition and
computational analysis. Such a program of research requires
an appropriate conceptual framework rich enough to capture
regulatory relationships but still tractable enough for large-scale
investigation. Furthermore, for practical application, such an
approach needs to be sufficiently robust to missing or unknown
variables. Causal models of the kind we discussed may provide
an appropriate framework because, unlike purely correlational
models, they allow for reasoning about change under interven-
tion and are, to a certain extent, robust to missing variables. In
particular, causal descendancy matrices (Figures 4A and S3)
are robust tomissing variables in the sense that addition of a pro-
tein (row) to the matrix would not change the existing entries. We
expect that a systematic program of investigation into context-
specific causal networks will be important in many disease
areas, and perhaps especially those that have to date not been
well represented in the literature.
Our results extend the well-established notion of genomic in-
tertumoral heterogeneity in cancer to the level of signaling
phenotype. We found that cell line-specific findings were more
reliable than stimulus-specific findings. This may be because
the magnitude of epigenetic and genetic differences between
cell lines is more marked than differences between stimuli, all
of which activate closely related cell-surface receptors.
Our approach relied on inhibitor specificity, but we note that
even at relatively low concentrations, off-target effects cannot be
entirely ruled out. However, if the inhibitors were highly non-spe-
cific, the relatively good results seen in the train-and-test analysis
would likely not be possible, since the analysis relies on assumed
inhibitor targets. In the future, itmayberelevant toconsidermodels
that allow uncertainty in the inhibitor targets themselves.
We highlighted the need to specify a relevant time frame in
defining a causal graph. Indeed, an inhibitor may in the short tolidation experiments. The first row indicates whether validation experiments
cted. The second and third rows concern the cell line and stimulus specificity of
h predictions from inferred networks; an orange tick denotes specificity, but not
were seen; and a red cross indicates that specificity was not observed in the
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medium term induce changes to specificmolecules, but over the
longer term, the same inhibitor might induce adaptive changes to
the cells themselves, e.g., via changes to epigenetic state (Dun-
can et al., 2012; Lee et al., 2012). We did not consider such ‘‘re-
wiring’’ in this article but note that the methods we discussed
could be used to study rewiring (e.g., by comparing networks
before and after adaptation).
In common with most protein profiling studies, including both
low- and high-throughput techniques, our experiments were
based on bulk assays and can therefore only elucidate signaling
heterogeneity at the level of cell populations; we did not consider
cell-to-cell heterogeneity, tumor stromal interactions, or the
spatial heterogeneity of tumors that plays an important role
in vivo (Bedard et al., 2013; Gonza´lez-Garcı´a et al., 2002). How-
ever, our data have implications for inter- and intra-tumoral het-
erogeneity, because they suggest the possibility that in vivo
causal signaling networks, and in turn the cell fates and disease
progression events that they influence, may depend on the local
micro-environment. Further work will be needed to elucidate
such dependence and draw out its implications.
In the future, causal molecular networks may start to play a
role in precision medicine, for example by helping to inform
rational assignment of targeted therapies. An implication of the
context specificity we report is that such analyses may require
models that are learned, or at least modified, for individual sam-
ples (or subsets of samples). Although causal models are in
some ways simpler than fully dynamical ones, causal inference
remains fundamentally challenging and is very much an open
area of research. For this reason, alongside advances in relevant
assays, a personalized, network-based approach will require
suitable empirical diagnostics. Hill et al. (2016) used the data pre-
sented here to score, in an automated manner, over 2,000 net-
works (70 methods each applied to infer 32 context-specific
networks) submitted to the HPN-DREAM network inference
challenge, and we used an extended version of this assessment
procedure here. Such assessment procedures might allow for
automated quality control, for example rejecting networks not
sufficiently consistent with unseen interventional readouts
(e.g., we did not obtain statistically significant performance un-
der any test inhibitor for the [BT549,EGF] context; see Figure S5).
However, as discussed in Hill et al. (2016) the assessment pro-
cedure remains limited in several ways, and this argues for
caution in interpreting the relatively good performance reported
here. Of particular relevance to context specificity, we note that
the procedure focuses on global agreement with held-out inter-
ventional data and not specifically on identification of differences
between contexts. Indeed, our validation experiments showed
that although all novel edges that were tested validated in one
or more contexts, network predictions were not accurate with
respect to the precise context(s) in which changes were seen.
Recently, Carvunis and Ideker (2014) proposed a view of
cellular function involving hierarchies of elements and processes
and not just networks. Building detailed dynamical or biophysical
models over hierarchies spanning multiple time and spatial
scales may prove infeasible. A more tractable approach may
be to extend coarser causal models of the kind used here in a hi-
erarchical direction, for example by allowing causal links to cross
scales and subsystems. Thus, the approach we pursued—of
causal models based on context-specific interventional data—82 Cell Systems 4, 73–83, January 25, 2017could in the future be used to populate models over biological
hierarchies.
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(clone 133D3)
Cell Signaling Technology Cat#2348; RRID: AB_2080326
Mouse monoclonal anti-Chk2 (clone 1C12) Cell Signaling Technology Cat#3440; RRID: AB_2229490
Rabbit monoclonal anti-phospho-Chk2 (Thr68)
(clone C13C1)
Cell Signaling Technology Cat#2197; RRID: AB_2080501
Rabbit polyclonal anti-cIAP-1/HIAP-2 Millipore Cat#07-759; RRID: AB_11212879
Rabbit polyclonal anti-Claudin-7 Novus Biologicals Cat#NB100-91714; RRID: AB_1216502
Rabbit polyclonal anti-Collagen-VI (clone H-200) Santa Cruz Cat#SC-20649; RRID: AB_2083098
Rabbit monoclonal anti-COX-2 (clone EP1978Y) Epitomics Cat#2169-1; RRID: AB_991710
Rabbit monoclonal anti-Cyclin-B1 (clone Y106) Epitomics Cat#1495-1; RRID: AB_562272
Rabbit polyclonal anti-Cyclin-D1 (clone M-20) Santa Cruz Cat#sc-718; RRID: AB_2070436
Mouse monoclonal anti-Cyclin-E1 (clone HE12) Santa Cruz Cat#sc-247; RRID: AB_627357
Rabbit monoclonal anti-DJ-1/PARK7 (clone EP2815Y) Abcam Cat#ab76008; RRID: AB_1310549
Rabbit polyclonal anti-Dvl3 Cell Signaling Technology Cat#3218; RRID: AB_10694060
Rabbit polyclonal anti-E-Cadherin Cell Signaling Technology Cat#4065; RRID: AB_2076803
Rabbit monoclonal anti-E-Cadherin (clone 24E10) Cell Signaling Technology Cat#3195; RRID: AB_10694492
Rabbit polyclonal anti-eEF2 Cell Signaling Technology Cat#2332; RRID: AB_10693546
Rabbit polyclonal anti-eEF2K Cell Signaling Technology Cat#3692; RRID: AB_10694413
Rabbit polyclonal anti-EGFR (clone 1005) Santa Cruz Cat#SC-03; RRID: AB_631420
Rabbit polyclonal anti-EGFR Cell Signaling Technology Cat#2232; RRID: AB_823483
Rabbit polyclonal anti-phospho-EGFR (Tyr1068) Cell Signaling Technology Cat#2234; RRID: AB_331701
Rabbit monoclonal anti-phospho-EGFR (Tyr1173) (E124) Epitomics Cat#1124; RRID: AB_344895
Rabbit polyclonal anti-phospho-EGFR_pY992 Cell Signaling Technology Cat#2235; RRID: AB_331709
Rabbit polyclonal anti-eIF4E Cell Signaling Technology Cat#9742; RRID: AB_823488
Rabbit polyclonal anti-eIF4G Cell Signaling Technology Cat#2498; RRID: AB_10692643
Rabbit monoclonal anti-ER-alpha (clone SP1) Lab Vision Cat#RM-9101-S; RRID: AB_149901
Rabbit monoclonal anti-phospho-ER-alpha (Ser118)
(clone E91)
Epitomics Cat#1091-1; RRID: AB_562111
Mouse monoclonal anti-ERCC1 (clone 8F1) Lab Vision Cat#MS-671-P0; RRID: AB_143360
Rabbit monoclonal anti-FAK (clone EP695Y) Epitomics Cat#1700-1; RRID: AB_562113
Rabbit monoclonal anti-Fibronectin (clone F14) Epitomics Cat#1574-1; RRID: AB_562115
Rabbit monoclonal anti-FoxM1 (clone D12D5) Cell Signaling Technology Cat#5436; RRID: AB_10692483
Rabbit polyclonal anti-FOXO3a Cell Signaling Technology Cat#9467; RRID: AB_10693643
Rabbit monoclonal anti-FOXO3a (clone 75D8) Cell Signaling Technology Cat#2497; RRID: AB_836876
Rabbit polyclonal anti-phospho-FOXO3a (Ser318/321) Cell Signaling Technology Cat#9465; RRID: AB_2106498
Rabbit monoclonal anti-Gab2 (clone 26B6) Cell Signaling Technology Cat#3239; RRID: AB_10698601
Mouse monoclonal anti-GATA3 (clone L50-823) BD Biosciences Cat#558686; RRID: AB_2108590
Mouse monoclonal anti-GSK3-alpha-beta (clone 0011-A) Santa Cruz Cat#sc-7291; RRID: AB_2279451
Rabbit polyclonal anti-phospho-GSK3-alpha-beta (Ser21/9) Cell Signaling Technology Cat#9331; RRID: AB_329830
Rabbit polyclonal anti-phospho-GSK3 (Ser9) Cell Signaling Technology Cat#9336; RRID: AB_331405
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Mouse monoclonal anti-HER2 Lab Vision Cat#MS-325-P1; RRID: AB_61444
Rabbit polyclonal anti-phospho-HER2 (Tyr1248) Upstate (Millipore) Cat#06-229; RRID: AB_310076
Rabbit polyclonal anti-HER3 (clone C-17) Santa Cruz Cat#sc-285; RRID: AB_2099723
Rabbit monoclonal anti-phospho-HER3 (Tyr1289)
(clone 21D3)
Cell Signaling Technology Cat#4791; RRID: AB_2099708
Rabbit polyclonal anti-IGF-1R-beta Cell Signaling Technology Cat#3027; RRID: AB_2122378
Rabbit polyclonal anti-IGFBP2 Cell Signaling Technology Cat#3922; RRID: AB_10691844
Goat polyclonal anti-INPP4B (clone N-20) Santa Cruz Cat#SC-12318; RRID: AB_2126126
Rabbit polyclonal anti-IRS1 Millipore Cat#06-248; RRID: AB_2127890
Rabbit monoclonal anti-phospho-JNK/SAPK
(Thr183/Tyr185) (clone 81E11)
Cell Signaling Technology Cat#4668; RRID: AB_823588
Rabbit polyclonal anti-JNK2 Cell Signaling Technology Cat#4672; RRID: AB_10695599
Mouse monoclonal anti-k-Ras (clone F234) Santa Cruz Cat#sc-30; RRID: AB_627865
Rabbit polyclonal anti-Lck Cell Signaling Technology Cat#2752; RRID: AB_10691548
Rabbit monoclonal anti-phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (clone 197G2)
Cell Signaling Technology Cat#4377; RRID: AB_331775
Rabbit monoclonal anti-MEK1 (clone Y77) Epitomics Cat#1235-1; RRID: AB_562310
Rabbit monoclonal anti-phospho-MEK1 (Ser217/221)
(clone 41G9)
Cell Signaling Technology Cat#9154; RRID: AB_2138017
Mouse monoclonal anti-MGMT (clone MT3.1) Millipore Cat#MAB16200; RRID: AB_2281919
Mouse monoclonal anti-MIG-6 Sigma-Aldrich Cat#WH0054206M1; RRID: AB_1841511
Rabbit monoclonal anti-Mre11 (clone 31H4) Cell Signaling Technology Cat#4847; RRID: AB_10693469
Mouse monoclonal anti-MSH2 (clone 3A2) Cell Signaling Technology Cat#2850; RRID: AB_2144797
Rabbit polyclonal anti-MSH6 Novus Biologicals Cat#22030002; RRID: AB_2266534
Rabbit monoclonal anti-mTOR (clone 7C10) Cell Signaling Technology Cat#2983; RRID: AB_2105622
Rabbit polyclonal anti-phospho-mTOR (Ser2448) Cell Signaling Technology Cat#2971; RRID: AB_330970
Rabbit polyclonal anti-MYH11 Novus Biologicals Cat#21370002; RRID: AB_2147162
Rabbit polyclonal anti-N-Cadherin Cell Signaling Technology Cat#4061; RRID: AB_10694647
Mouse monoclonal anti-N-Ras (clone F155) Santa Cruz Cat#sc-31; RRID: AB_628041
Rabbit polyclonal anti-phospho-NDRG1 (Thr346) Cell Signaling Technology Cat#3217; RRID: AB_2150174
Rabbit monoclonal anti-phospho-NF-kB-p65 (Ser536) Cell Signaling Technology Cat#3033; RRID: AB_331284
Rabbit polyclonal anti-NF2 SDI / Novus Cat#2271.00.02; RRID: AB_2298264
Rabbit monoclonal anti-Notch1 (clone C44H11) Cell Signaling Technology Cat#3268; RRID: AB_1264224
Rabbit polyclonal anti-Notch3 (clone M-134) Santa Cruz Cat#sc-5593; RRID: AB_2151246
Rabbit polyclonal anti-P-Cadherin Cell Signaling Technology Cat#2130; RRID: AB_10693468
Rabbit polyclonal anti-p21 (clone C-19) Santa Cruz Cat#sc-397; RRID: AB_632126
Rabbit monoclonal anti-p27/Kip1 (clone Y236) Epitomics Cat#1591-1; RRID: AB_562357
Rabbit polyclonal anti-phospho-p27/Kip1 (Thr157) R&D Systems Cat#AF1555; RRID: AB_354857
Rabbit polyclonal anti-phospho-p27/KIP 1 (Thr198) Abcam Cat#ab64949; RRID: AB_1142099
Rabbit polyclonal anti-p38 MAPK Cell Signaling Technology Cat#9212; RRID: AB_330713
Rabbit polyclonal anti-phospho-p38 MAPK (Thr180/Tyr182) Cell Signaling Technology Cat#9211; RRID: AB_331641
Rabbit polyclonal anti-p53 Cell Signaling Technology Cat#9282; RRID: AB_10693944
Rabbit monoclonal anti-p70S6K (clone E343) Epitomics Cat#1494-1; RRID: AB_562325
Rabbit polyclonal anti-phospho-p70S6K (Thr389) Cell Signaling Technology Cat#9205; RRID: AB_330944
Rabbit polyclonal anti-phospho-p90RSK (Thr359/Ser363) Cell Signaling Technology Cat#9344; RRID: AB_331650
Mouse monoclonal anti-PARP (cleaved D214) (clone 19F4) Cell Signaling Technology Cat#9546; RRID: AB_2160593
Rabbit monoclonal anti-Paxillin (clone Y113) Epitomics Cat#1500-1; RRID: AB_562188
Mouse monoclonal anti-PCNA (clone PC10) Abcam Cat#ab29; RRID: AB_303394
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Rabbit polyclonal anti-PDCD4 Rockland Cat#600-401-965; RRID: AB_828370
Rabbit polyclonal anti-PDK1 Cell Signaling Technology Cat#3062; RRID: AB_10695863
Rabbit polyclonal anti-phospho-PDK1 (Ser241) Cell Signaling Technology Cat#3061; RRID: AB_2161311
Rabbit polyclonal anti-PEA15 Cell Signaling Technology Cat#2780; RRID: AB_2268149
Rabbit polyclonal anti-phospho-PEA15 (Ser116) Invitrogen Cat#44-836G; RRID: AB_2533775
Rabbit polyclonal anti-PI3K-p110-alpha Cell Signaling Technology Cat#4255; RRID: AB_10695395
Rabbit polyclonal anti-PI3K_p85 Millipore Cat#06-195; RRID: AB_310069
Mouse monoclonal anti-PKC-alpha (clone M4) Millipore Cat#05-154; RRID: AB_2284233
Rabbit polyclonal anti-phospho-PKC-alpha (Ser657) Millipore Cat#06-822; RRID: AB_310258
Rabbit polyclonal anti-phospho-PKC-delta (Ser664) Millipore Cat#07-875; RRID: AB_568868
Rabbit polyclonal anti-phospho-PKC-pan-betaII (Ser660) Cell Signaling Technology Cat#9371; RRID: AB_2168219
Rabbit monoclonal anti-PR (clone YR85) Epitomics Cat#1483-1; RRID: AB_562201
Rabbit polyclonal anti-phospho-PRAS40 (Thr246) Biosource Cat#441100G; RRID: AB_2533573
Rabbit polyclonal anti-PTCH SDI Cat#21130002; RRID: AB_876276
Rabbit polyclonal anti-PTEN Cell Signaling Technology Cat#9552; RRID: AB_10694066
Rabbit polyclonal anti-Rab11 Cell Signaling Technology Cat#3539; RRID: AB_2253210
Rabbit polyclonal anti-Rab25 Covance (custom antibody
services)
N/A
Mouse monoclonal anti-Rad50 (clone 13B3/2C6) Millipore Cat#05-525; RRID: AB_309782
Mouse polyclonal anti-Rad51 Chem Biotech Cat#na 71
Rabbit monoclonal anti-Raptor (24C12) Cell Signaling Technology Cat#2280; RRID: AB_10694695
Mouse monoclonal anti-Rb (clone 4H1) Cell Signaling Technology Cat#9309; RRID: AB_823629
Rabbit polyclonal anti-phospho-Rb (Ser807/811) Cell Signaling Technology Cat#9308; RRID: AB_331472
Rabbit polyclonal anti-RBM15 Novus Biologicals Cat#21390002; RRID: AB_2175759
Rabbit monoclonal anti-Rictor (clone 53A2) Cell Signaling Technology Cat#2114; RRID: AB_10694641
Rabbit monoclonal anti-phospho-Rictor (Thr1135)
(clone D30A3)
Cell Signaling Technology Cat#3806; RRID: AB_10557237
Rabbit polyclonal anti-phospho-S6 (Ser235/236) Cell Signaling Technology Cat#2211; RRID: AB_331679
Rabbit polyclonal anti-phospho-S6 (Ser240/244) Cell Signaling Technology Cat#2215; RRID: AB_331682
Mouse monoclonal anti-SCD1 (clone CD.E10) Santa Cruz Cat#sc-58420; RRID: AB_785599
Mouse monoclonal anti-SF2 (clone 96) Invitrogen Cat#32-4500; RRID: AB_2533079
Mouse monoclonal anti-Smac/Diablo Cell Signaling Technology Cat#2954; RRID: AB_10694396
Rabbit monoclonal anti-Smad1 (clone EP565Y) Epitomics Cat#1649-1; RRID: AB_562224
Rabbit monoclonal anti-Smad3 (clone EP568Y) Epitomics Cat#1735-1; RRID: AB_598188
Mouse polyclonal anti-Smad4 (clone B-8) Santa Cruz Cat#sc-7966; RRID: AB_627905
Mouse polyclonal anti-Snail (clone L70G2) Cell Signaling Technology Cat#3895; RRID: AB_2191759
Mouse monoclonal anti-Src (clone GD11) Millipore Cat#05-184; RRID: AB_2302631
Rabbit polyclonal anti-phospho-Src (Tyr416) Cell Signaling Technology Cat#2101; RRID: AB_331697
Rabbit polyclonal anti-phospho-Src (Tyr527) Cell Signaling Technology Cat#2105; RRID: AB_331034
Rabbit polyclonal anti-phospho-STAT3 (Tyr705) Cell Signaling Technology Cat#9131; RRID: AB_331586
Rabbit monoclonal anti-STAT5-alpha (E289) Epitomics Cat#1289-1; RRID: AB_562347
Rabbit monoclonal anti-Stathmin (clone EP1573Y) Epitomics Cat#1972-1; RRID: AB_991829
Mouse monoclonal anti-Syk (clone 4D10) Santa Cruz Cat#sc-1240; RRID: AB_628308
Mouse monoclonal anti-Tau (clone 5E2) Millipore Cat#05-348; RRID: AB_309687
Rabbit polyclonal anti-TAZ Cell Signaling Technology Cat#2149; RRID: AB_823657
Rabbit polyclonal anti-phospho-TAZ (Ser89) Santa Cruz Cat#sc-17610; RRID: AB_671263
Rabbit polyclonal anti-TIGAR Epitomics Cat#S1711; RRID: AB_10638379
Mouse monoclonal anti-Transglutaminase II Lab Vision Cat#MS-224-P1; RRID: AB_62205
(Continued on next page)
Cell Systems 4, 73–83.e1–e10, January 25, 2017 e4
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Rabbit polyclonal anti-TFRC Novus Biologicals Cat#22500002; RRID: AB_10004660
Rabbit polyclonal anti-TSC1 Cell Signaling Technology Cat#4906; RRID: AB_10695257
Rabbit monoclonal anti-TTF1 (clone EP1584Y) Epitomics Cat#2044-1; RRID: AB_1267367
Rabbit monoclonal anti-Tuberin (clone Y320) Epitomics Cat#1613-1; RRID: AB_562354
Rabbit polyclonal anti-VASP Cell Signaling Technology Cat#3112; RRID: AB_10693778
Rabbit monoclonal anti-VEGFR2 (clone 55B11) Cell Signaling Technology Cat#2479; RRID: AB_2212507
Mouse monoclonal anti-VHL (clone Ig32) BD Biosciences Cat#556347; RRID: AB_396376
Rabbit polyclonal anti-XIAP Cell Signaling Technology Cat#2042; RRID: AB_2214868
Rabbit polyclonal anti-XRCC1 Cell Signaling Technology Cat#2735; RRID: AB_2218471
Rabbit polyclonal anti-YAP (clone H-125) Santa Cruz Cat#sc-15407; RRID: AB_2273277
Rabbit polyclonal anti-phospho-YAP (Ser127) Cell Signaling Technology Cat#4911; RRID: AB_2218913
Rabbit polyclonal anti-YB-1 SDI / Novus Cat#1725.00.02; RRID: AB_936227
Rabbit monoclonal anti-phospho-YB-1 (Ser102)
(clone C34A2)
Cell Signaling Technology Cat#2900; RRID: AB_2219273
Mouse monoclonal anti-beta-Actin (clone C4) Santa Cruz Cat#SC-47778; RRID: AB_626632
Mouse monoclonal alpha-Tubulin (clone B-5-1-2) Invitrogen Cat#322500; RRID: AB_2533071
Mouse monoclonal anti-Hsp90 (clone 68) Transduction Laboratories Cat#H38220; RRID: AB_397798
HRP Donkey polyclonal anti-mouse Jackson Immunoresearch Cat#715-035-150; RRID: AB_2340770
HRP Donkey polyclonal anti-rabbit Jackson Immunoresearch Cat#711-035-152; RRID: AB_10015282
Chemicals, Peptides, and Recombinant Proteins
AZD8055 Selleck Cat#S1555
GSK690693 Selleck Cat#S1113
BEZ235 Selleck Cat#S1009
PD173074 Selleck Cat#S1264
GSK1120212 Selleck Cat#S2673
AZD7762 Selleck Cat#S1532
KX2-391 Selleck Cat#S2700
PF4708671 Selleck Cat#S2163
VX-702 Selleck Cat#S6005
DMEM GIBCO Cat#11965-118
RPMI GIBCO Cat#11875-119
Fetal Bovine Serum GIBCO Cat#10437
HGF GIBCO Cat#PHG0254
FGF-alpha GIBCO Cat#PHG0014
Insulin Sigma Cat#IO516-5ML
IGF GIBCO Cat#PHG0078
NRG-1 R&D Systems Cat#5898-R
EGF GIBCO Cat#PHG0311
cOmplete protease inhibitor cocktail Roche Applied Science Cat# 4693116001
phosSTOP phosphatase inhibitor cocktail Roche Applied Science Cat# 4906845001
Critical Commercial Assays
SuperSignal West Pico Chemiluminescent HRP
Substrate Kit
Thermofisher Scientific Cat#34080
Pierce BCA Protein Assay Thermofisher Scientific Cat#23225
Deposited Data
RPPA data This paper Data S1 and S2
Experimental Models: Cell Lines
Human: MCF7 cells ATCC: HTB-22 Cat#HTB-22; RRID:CVCL_0031
Human: UACC812 cells ATCC: CRL-1897 Cat#CRL-1897; RRID:CVCL_1781
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Human: BT20 cells ATCC: HTB-19 Cat#HTB-19; RRID:CVCL_0178
Human: BT549 cells ATCC: HTB-122 Cat#HTB-122; RRID:CVCL_1092
Software and Algorithms
Scripts for: identification of changes under kinase
inhibition, network learning and assessment of network
learning performance
This paper (see
STAR Methods for details)
https://github.com/Steven-M-Hill/causal-
signaling-networks-CellSystems2016
MATLAB R2012a MathWorks, Inc. http://www.mathworks.com
DataRail Saez-Rodriguez et al., 2008 https://code.google.com/archive/
p/sbpipeline/
Cytoscape Shannon et al., 2003 http://www.cytoscape.org/
Joint Network Inference (modified version used in this paper;
script available on github, see above)
Oates et al., 2014 http://dx.doi.org/10.1214/14-AOAS761
Supercurve Coombes et al., 2012 http://bioinformatics.mdanderson.org/
Software/supercurve/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents and resources may be directed to, and will be fulfilled by, the Lead Contact Paul
T. Spellman (spellmap@ohsu.edu).
EXPERIMENTAL MODEL DETAILS
Breast epithelial cells in log-phase of growth were harvested, diluted in the appropriate media (DMEM (with phenol red) for
UACC812, BT20 and MCF7; RPMI (with phenol red) for BT549) containing 10% fetal bovine serum, and then seeded into
6 well plates at an optimized cell density (to give 60%–75% confluence at time of lysis). BT20 cells were plated at 230,000
cells/well; BT549 cells were plated at 175,000 cells/well; MCF7 cells were plated at 215,000 cells/well; and UACC812 cells
were plated at 510,000 cells/well. After 24 hr of growth at 37C and 5% CO2 in complete medium, cells were synchronized
by incubating with serum-free medium for an additional 24 hr (serum starvation was also necessary to control the presence
of stimuli in the medium). The medium was then exchanged with fresh serum-free medium containing either: 15nM AZD8055,
50nM GSK690693, 50nM BEZ235, 150nM PD173074, 10nM GSK1120212 in combination with 50nM GSK690693, or vehicle
alone (0.05% DMSO) and incubated for two hours prior to stimulation. Cells were then either harvested (0 time point) or stim-
ulated by addition of 200 mL per well of 10X stimulus (either PBS, fetal bovine serum, 100 ng/mL EGF, 200ng/mL IGF1, 100nM
insulin, 200ng/mL FGF1, 1 mg/mL NRG1, or 500 ng/mL HGF) for 0, 5, 15, 30 or 60 min, or 2, 4, 12, 24, 48 or 72 hr prior to protein
harvest.
All cell lines have been authenticated by performing STR analysis and matching to reference STR profiles at 15 different loci. STR
analysis was performed by Genetica Cell Line Testing.
METHOD DETAILS
Preparation of Cells for RPPA Analysis
Cells were grown as described above, then washed twice with PBS and lysed by adding lysis buffer obtained from MD Anderson
Functional Proteomics RPPA Core Facility (Houston, Texas; lysis buffer comprised 1% Triton X-100, 50mM HEPES,
pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol; prote-
ase and phosphatase inhibitors were freshly added on the day of the experiment). Volume of lysis buffer used was optimized for
each cell line (to ensure lysates were not too dense for the BCA assay; see below) and varied between 50 mL and 100 mL. Lysates
were collected by scraping after 20 min incubation on ice. Lysates were spun at 4C in a tabletop centrifuge at 15,000 RPM for
10 min and soluble proteins contained in the supernatant were collected. Protein concentration was determined by the Pierce
BCA Protein Assay according to manufacturer’s protocol. Protein was then diluted to 1 mg/mL and 30 mL of the diluted lysate
was mixed with 10 mL 4X SDS sample buffer (obtained from MD Anderson Functional Proteomics RPPA Core Facility; comprised
40% Glycerol, 8% SDS, 0.25M Tris-HCL, pH 6.8; 10% v/v 2-mercaptoethanol was added fresh) and boiled for 5 min prior to
freezing and shipment to MD Anderson Cancer Center Functional Proteomics RPPA Core Facility for RPPA analysis (Tibes
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RPPA Methodology
RPPA methodology has been described previously (see e.g., Akbani et al., 2014); an outline is also provided below. Lysates were
diluted in five two-fold serial dilutions with lysis buffer. An Aushon Biosystems 2470 arrayer (Burlington, MA) was used to print
1056 samples and control lysates on nitrocellulose-coated slides (Grace Bio-Labs). Each slide was probed with a primary antibody
and a biotin-conjugated secondary antibody. Antibodies go through a validation process as previously described (Hennessy et al.,
2010) to assess specificity, quantification and dynamic range. Each of the 183 primary antibodies was assigned a label based on this
validation process (at the time the assay was performed): ‘‘validated,’’ ‘‘use with caution’’ or ‘‘under evaluation’’ (see Table S1). Sam-
ples were split across three batches and some antibodies were used only in a subset of these batches (Table S1). A DakoCytomation-
catalyzed system and DAB colorimetric reaction was used to capture signal. Following scanning of slides, spot intensities were
analyzed and quantified using Microvigene software (VigeneTech). The EC50 values of the proteins in each dilution series were esti-
mated using the SuperCurve software (Coombes et al., 2012), available at http://bioinformatics.mdanderson.org/Software/
supercurve/. This uses the non-parametric, monotone increasing B-spline model (Hu et al., 2007) to fit a single curve (‘‘supercurve’’)
using all samples on a slide, with signal intensity as the response variable and dilution step as the independent variable. The fitted
curve is plotted with the signal intensities on the y axis and the log2 protein concentrations on the x axis for diagnostic purposes.
A quality control (QC) metric, between zero and one was calculated for each slide (Coombes et al., 2012) and slides with values
less than 0.8 were excluded. Within each batch, measurements were normalized for protein loading by median centering across
antibodies (Liu et al., 2014; Li et al., 2013). This normalization process, performed on log2 concentrations, comprised the following
steps:
1. For each antibody, calculate the median across samples and subtract from each value (i.e., median-center each antibody).
2. For each sample, calculate the median across antibodies to obtain a correction factor (CF).
3. For each sample, take the original log2 concentration values and subtract the corresponding CF (from step 2).Normalized values, on a linear scale, are provided in Data S1.Western Blot Analysis
Cells were grown as described above. For the novel edge validations in Figure 6, additional inhibitors were used to generate ly-
sates following the protocol laid out above. The inhibitors, all used at 1 mM, were AZD7762, KX2-391, PF4708671, and VX-702
(see Figure 6 for targets). In experiments designed to test the range of concentrations that were effective, 1 mM was able to
trigger changes in the phosphorylation of proteins downstream of the inhibitor targets. Lysates were harvested 15 min after stim-
ulation and protein concentrations quantified as described above. Denatured lysates were separated by PAGE on 4%–12% Bis-
Tris gradient gels (Invitrogen) along with Precision Plus Protein Standards (Bio-Rad) using MOPS SDS NuPAGE Running Buffer
(Invitrogen) and NuPAGE LDS Sample Buffer (Invitrogen) on ice at 200 V for 45 min. Gels were transferred to immobilin-FL PVDF
membranes (Millipore) using NuPAGE Transfer Buffer (Invitrogen) on ice at 30 V for 1.5 hr before being washed 3x 5 min. with 5%
Tween-TBS (TTBS, Amresco & Invitrogen) at room temperature (RT) with agitation and blocked with 5% BSA (Sigma) in TTBS
for 1 hr at RT with agitation. Blots were again washed 3x 5 min in TTBS at RT with agitation before being incubated in primary
antibody in 5% BSA in TTBS overnight at 4C with agitation. Blots were washed 3x for 5 min at RT with agitation and then trans-
ferred to HRP-conjugated secondary antibody in 5% BSA in TTBS and incubated at RT for 1.5 hr. See Table S5 for primary
antibodies and HRP-conjugated secondary antibodies used in western blot validations. Blots were washed again as previ-
ously described and visualized using SuperSignal West Pico Chemiluminescent HRP Substrate Kit (Thermo Scientific) and
CL-X Posure Film (Thermo Scientific) and changes in protein abundance under inhibition were determined by visual inspection
of exposed film.
Quality Control and Preprocessing of RPPA Data
Batch Normalization Procedure for Cell Line UACC812
The UACC812 data were split across two RPPA experiments with each batch containing different inhibitors (BEZ235, PD173074 and
GSK690693&GSK1120212 in one batch; AZD8055 and GSK690693 in the other). DMSO control samples were common to both
batches. The two batches were combined and normalized to obtain a single dataset for UACC812.
The steps of the batch normalization procedure were as follows:
1. Any antibodies not included in both batches were removed.
For each antibody, perform steps 2 and 3 below.
2. Using log2-transformed data (after normalization for protein loading; see above), themean and standard deviation of the DMSO
samples in each batch were calculated, giving values (m1, s1) and (m2, s2) for batch 1 and batch 2 respectively. Note that, for
each batch, there are 16 replicates for DMSO, 0min samples (all other DMSO conditions consist of a single replicate). These
16 replicates were averaged prior to calculation of mean values and standard deviations.e7 Cell Systems 4, 73–83.e1–e10, January 25, 2017
3. All samples inbatch2 (for thegivenantibody)were thenscaledandcenteredso that themeanandstandarddeviationof thebatch
2 DMSO samples agreed with the corresponding batch 1 quantities (m1, s1). That is, a sample in batch 2 with value x becamem1 +
s1ðx  m2Þ
s2
:
This scaling and centering was applied to each individual replicate and not to replicate-averaged data.
4. The two batches were then combined to get a single dataset for UACC812.
Data for the two batches and the final normalized dataset are provided in Data S1 on a linear scale.
Samples Excluded from Analyses
Samples identified as outliers were excluded from our analyses. These samples were identified using the following criteria:
d Normalization for protein loading resulted in a correction factor (CF) for each sample (see above). Samples with CF > 2.5 or
CF < 0.25 were regarded as outliers.
d Variance across all antibodies was calculated for each sample. Values greater than 40 were regarded as outliers.
d We used the replicates at time t = 0 to calculate the signal-to-noise ratio (SNR) for each cell line and phosphoprotein antibody
under each inhibitor (mean of replicates divided by standard deviation of replicates). The mean across all calculated SNRs was
10.68 (s.d. = 5.8). SNR values less than 1 were investigated further to determine whether the poor SNR was caused by outlier
replicates.
For cell line UACC812, these criteria were applied to the batch-normalized dataset.
In addition to the above, data for the combination of inhibitors GSK690693 & GSK1120212 (AKTi & MEKi) for cell lines BT549
(all stimuli) and BT20 (PBS and NRG1 stimuli only) were excluded since none of the expected effects of MEKi were observed in these
samples.
All samples excluded from analyses are shown in Table S6 and also indicated in the data files in Data S1.
Antibodies Included in Analyses
To facilitate comparisons between cell lines, the analyses presented here focused on the set of phosphoprotein antibodies common
to all four lines. This set contained two highly correlated pairs of antibodies (r > 0.9 for all cell lines), consisting of phosphoforms of the
same protein: GSK3ab_pS21_pS9, GSK3_pS9 and S6_pS235_S236, S6_pS240_S244. Since highly correlated variables can lead to
a reduction in the utility of network inference results, only one antibody out of each pair was included in analyses, resulting in a final set
of 35 phosphoprotein antibodies. A full list of antibodies can be found in Table S1, where the 35 phosphoproteins included in the
analyses are also indicated.
Final Preprocessing Steps
Data were log2 transformed and replicates (only present for t = 0 samples and some DMSO samples) were averaged. Prior to input
into our network inference pipeline, imputation was performed for missing data by linear interpolation of adjacent time points.
Identification of Changes Under Kinase Inhibition
We used a procedure centered on paired t tests to determine which phosphoproteins show a salient change in abundance under
each kinase inhibitor. Details are described in Hill et al. (2016), but also outlined below for completeness.
For each phosphoprotein, inhibitor regime and (cell line, stimulus) context, a paired t test was used to assess whether mean phos-
phoprotein abundance under DMSO control is significantly different to mean abundance under the inhibitor regime (mean values
calculated over seven time points). As discussed above, some phosphoproteins show a clear response to the stimulus under
DMSO control, with abundance increasing and then decreasing over time (a ‘‘peak’’ shape), while others show a less clear response
due to signal already being present prior to stimulus. For phosphoproteins falling into the former category (according to a heuristic),
paired t tests were repeated, but this time restricted to intermediate time points within the peak. This focuses on the portion of the
time course where an inhibition effect, if present, should be seen. The p-value from the repeated test was retained if smaller than the
original p-value. For each (cell line, stimulus) context and inhibitor regime, the resulting set of p-values (one p-value for each phos-
phoprotein) were corrected for multiple testing using the adaptive linear step-up procedure for controlling the FDR (Benjamini et al.,
2006).
For each (cell line, stimulus) context, a phosphoprotein was deemed to show a salient change under a given inhibitor regime if two
conditions were satisfied. First, the corresponding FDR value had to be less than 5% and, second, the effect size (log2 ratio between
DMSO control and inhibitor conditions) had to be sufficiently large relative to replicate variation (see Figure S2). The latter condition is
an additional filter to remove small effects. Replicate variationwas quantified by calculating the pooled replicate standard deviation at
each time point of the DMSO and inhibitor time courses, and then averaging these values across time points. The phosphoproteins
satisfying these criteria are depicted in Figures 3B, 4A, and S1–S3. We note that the overall procedure is heuristic and that the FDR
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A phosphoprotein p showing a salient change under an inhibitor is consistent with a node targeted by the inhibitor having a causal
effect on the phosphoprotein. Since this effect can be direct or indirect, phosphoprotein p can be regarded as a descendant of the
inhibitor target node in the underlying signaling network. That is, there exists a directed path starting from the node targeted by the
inhibitor and ending at phosphoprotein p.
Network Learning
Networks were learned for each of the 32 (cell line, stimulus) contexts using dynamic Bayesian networks (DBNs), a type of probabi-
listic graphical model for time-course data (see e.g., Hill et al., 2012; Husmeier, 2003; Murphy, 2002). Specifically we used a recently
proposed variant called interventional DBNs or iDBNs (Spencer et al., 2015), that uses ideas from causal inference (Pearl, 2009;
Spirtes et al., 2000) to model interventions and thereby improve ability to infer causal relationships; model specification followed
Spencer et al. (2015). Although interested in learning context-specific networks, we expect a good proportion of agreement between
contexts. Therefore, rather than learn networks for each context separately, we used a recently developed joint learning approach to
solve all the problem instances together (Oates et al., 2014). A prior network was used (Figure S4); this was curated manually with
input from literature (Weinberg, 2013) and online resources. The extent to which context-specific networks are encouraged to agree
with each other and with the prior network is controlled by two parameters, l and h respectively, as described in detail in Oates et al.
(2014). These parameters were set (to l= 3 and h= 15) by considering a grid of possible values and selecting an option that provides a
reasonable, but conservative amount of agreement, allowing for discovery of context-specific edges that are not in the canonical
prior network. The network learning approach resulted in a score (edge probability) for each possible edge in each context-specific
network. The network estimates were robust to moderate data deletion and precise specification of the biological prior network and
its strength (Figure S6). Furthermore, the analyses were computationally efficient, requiring approximately 30 min to learn all
32 context-specific networks using serial computation on a standard personal computer (Intel i7-2640M 2.80GHz processor,
8GB RAM).
Assessing Performance of Causal Network Learning
The ability of our network learning approach to estimate context-specific causal networks was systematically assessed using a train
and test scheme proposed by Hill et al. (2016) in the context of the HPN-DREAM network inference challenge associated with the
RPPA data presented here. Due to factors specific to the challenge setting, Hill et al. (2016) used only a single iteration of train
and test. In contrast, we were able to perform several iterations, as described below.
In each iteration, the data were divided into two sets: (i) a test dataset, consisting of time courses for all 32 (cell line, stimulus) con-
texts under a single inhibitor regime, and (ii) a training dataset, consisting of time courses (again for all 32 contexts) for a subset of the
remaining five inhibitor regimes (Figure S5A). We refer to the single inhibitor regime in the test data as the test inhibitor (although note
that one regime contains more than one kinase inhibitor: GSK690693 & GSK1120212). Thirty-two context-specific networks were
learned on the training dataset and then each network was assessed as to how well it agreed with changes observed, for the
same context, under the test inhibitor (in the test dataset). For each test inhibitor, the set of phosphoproteins that show, for a given
context, a salient change in abundance were determined as described above (and shown in Figures 4A and S3), resulting in context-
specific ‘‘gold-standard’’ descendant sets. We then compared, for each context, predicted descendants of the test inhibitor target
node(s) according to the network inferred from training data, against the corresponding ‘‘gold-standard’’ descendant set. This re-
sulted in a number of correctly predicted descendants (true positives, TPs) and a number of incorrectly predicted descendants (false
positives, FPs). Our network learning approach outputs edge probabilities, from which a network can be obtained using a threshold
value. The TP and FP values were therefore a function of this threshold value, resulting in an ROC (receiver operating characteristic)
curve. Our final assessment metric was then the area under this curve (AUROC), which we calculated for each context and test in-
hibitor (Figure S5B). The statistical significance of the AUROC scores was determined using an empirical null distribution, generated
by calculating AUROC scores for sets of uniformly random edge probabilities.
The assessment procedure requires that nodes targeted by the test inhibitor are present in the network model so that their descen-
dants can be determined. Also, it is important that the training data only contains inhibitor regimes that target nodes which are not
also targeted by the test inhibitor. There were three train and test data splits that satisfied these criteria (while also maximizing the
sample size of the training dataset), and we assessed performance for all three (Figure S5B).
QUANTIFICATION AND STATISTICAL ANALYSIS
Replicates were averaged prior to carrying out statistical analysis and the time courses shown in Figures 3 and S1 were plotted using
replicate-averaged data.
The number of replicates were as follows: 16 replicates for samples at t = 0, except for UACC812, BT20 and MCF7 DMSO t = 0
samples which were replicated32 times; 2 replicates for themajority of DMSO samples at t > 0, except for BT20 DMSO samples; all
other samples had a single replicate.
Details of statistical procedures are provided in the methods section above or in figure legends. Analyses were performed using
MATLAB R2012a software.e9 Cell Systems 4, 73–83.e1–e10, January 25, 2017
DATA AND SOFTWARE AVAILABILITY
Software
Scripts for the computational and statistical analyses presented here are available at https://github.com/Steven-M-Hill/
causal-signaling-networks-CellSystems2016. These scripts include identification of changes under kinase inhibition, network
learning, and assessment of network learning performance.
Data Resources
RPPA data, including additional time points and antibodies that were not used in the analyses presented here, are provided in Data
S1. Time-course plots for all of the antibodies are provided in Data S2.
ADDITIONAL RESOURCES
HPN-DREAM network inference challenge associated with the RPPA data presented here: https://www.synapse.org/HPN_
DREAM_Network_Challenge.Cell Systems 4, 73–83.e1–e10, January 25, 2017 e10
